Добірка наукової літератури з теми "Survie sans récidive"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Survie sans récidive".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Survie sans récidive":
Guillemin, F., F. Marchal, and M. Geffroy. "Évaluation d’un second traitement chirurgical conservateur pour récidive locale d’un cancer du sein." Oncologie 21, no. 1-4 (January 2019): 22–28. http://dx.doi.org/10.3166/onco-2019-0028.
Poghosyan, T., A. Dechartres, M. Chirica, J. Villa, N. Munoz-Bongrand, P. Cattan, and E. Sarfati. "Survie sans récidive après chirurgie dans le cancer de l’œsophage (422)." Journal de Chirurgie Viscérale 147, no. 4 (September 2010): 22–23. http://dx.doi.org/10.1016/s1878-786x(10)70050-4.
Xylinas, E., M. Rink, V. Margulis, Y. Lotan, M. Zerbib, and S. Shariat. "Outil de prédiction de la survie sans récidive et de la survie spécifique des patients pT1-T3N0 après cystectomie radicale." Progrès en Urologie 22, no. 13 (November 2012): 761. http://dx.doi.org/10.1016/j.purol.2012.08.048.
Prost, P., M. Duraes, V. Georgescu, L. Rebel, G. Mercier, and G. Rathat. "Impact du volume de chirurgies du centre sur la survie globale et la survie sans récidive de patientes atteintes d'un cancer de l'ovaire." Journal of Epidemiology and Population Health 72 (March 2024): 202349. http://dx.doi.org/10.1016/j.jeph.2024.202349.
Dieng, MM, NF Kane Ba, N. Ben Amor, EHA Baldé, A. Dem, PM Gaye, and L. Kochbati. "C116: Toxicité cutanée tardive après radiothérapie hypo-fractionnée des cancers du sein post-mastectomie : A propos de 40 cas." African Journal of Oncology 2, no. 1 Supplement (March 1, 2022): S48. http://dx.doi.org/10.54266/ajo.2.1s.c116.veof2707.
Koupparis, Anthony J., Jeremy P. Grummet, Antonio Hurtado-Coll, Robert H. Bell, Nicholas Buchan, Larry Goldenberg, and Martin E. Gleave. "Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series." Canadian Urological Association Journal 5, no. 6 (April 15, 2013): 156. http://dx.doi.org/10.5489/cuaj.762.
Raillat, J., J. Grillot, A. Vienot, D. Vernerey, F. Fein, C. Turco, B. Heyd, et al. "Valeur prédictive de la sarcopénie et de la lymphopénie préopératoires sur la survie sans récidive dans l’adénocarcinome pancréatique opérable." Nutrition Clinique et Métabolisme 33, no. 1 (March 2019): 66. http://dx.doi.org/10.1016/j.nupar.2019.01.343.
Roux, V., R. Eyraud, L. Brureau, G. Gourtaud, C. Senechal, M. Fofana, and P. Blanchet. "Impact du score de Gleason sur la survie sans récidive biologique après prostatectomie totale pour cancer avec marges chirurgicales positives." Progrès en Urologie 27, no. 8-9 (June 2017): 467–73. http://dx.doi.org/10.1016/j.purol.2017.05.003.
Mamelle, E., and D. Hartl. "Impact de l’évidement ganglionnaire cervical prophylactique sur la survie sans récidive et le retraitement des carcinomes différenciés de la thyroïde." Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale 130, no. 4 (October 2013): A63. http://dx.doi.org/10.1016/j.aforl.2013.06.528.
MALGRAS, B., X. DURAND, A. SALIN, M. DUSAUD, B. MOLINARD, and A. HOULGATTE. "Prise en charge des tumeurs du rein de petite taille: étude à propos de 91 néphrectomies partielles." Médecine et Armées Vol. 41 No. 3, Volume 41, Numéro 3 (June 1, 2013): 271–76. http://dx.doi.org/10.17184/eac.6684.
Дисертації з теми "Survie sans récidive":
Eberst, Guillaume Nicolas. "Seconds cancers après traitement curatif d'un cancer broncho-pulmonaire." Electronic Thesis or Diss., Bourgogne Franche-Comté, 2023. http://www.theses.fr/2023UBFCE029.
The first objective of the 2014-2019 cancer plan was to cure more patients by promoting earlier diagnosis. This objective gives hope for more diagnosis at early stages accessible to surgical resection. Currently, excisional surgery for non-small cell bronchopulmonary cancer (NSCLC) is the treatment offering the most hope for a cure. This thesis work is particularly interested in the future of operated patients.Despite a curative intention, patients operated on for NSCLC are at risk of recurrence of the operated cancer but also have a higher risk of second cancer, and in particular second primary lung cancer (SPLC), higher than that of the general population. , of the order of 20% cumulative incidence at 10 years.When a lung lesion with the same histological diagnosis as the operated cancer occurs, the differential diagnosis between recurrence of the operated cancer or SPLC is difficult. Several definitions exist. Based on the hypothesis that recurrences indicate an aggressiveness of the cancerous disease, and therefore most often have a worse prognosis than second cancers, we first conducted a Cochrane systematic review of the set of definitions used in the literature in order to identify the one which offers the best prognostic distinction, on which to base the differential diagnosis between recurrence of operated cancer and SCBP.A few years ago, immunotherapy established itself in the therapeutic arsenal for bronchopulmonary cancer. First used in the metastatic situation, immunotherapy is now tested in the perioperative situation in numerous trials. However, due to the diversity of combinations and therapeutic strategies, not all of which have been compared with each other, uncertainty remains regarding the best perioperative therapy for patients undergoing surgery for early-stage NSCLC. We initiated a systematic review of interventional trials with network meta-analysis according to the Cochrane method on the effectiveness of these perioperative treatments in patients with non-small cell lung cancer.The IFCT-0302 study is the only large randomized surveillance study of NSCLC patients. It included 1775 patients. Its objective was to compare the overall survival of two monitoring strategies: by clinic and chest x-rays in the control group, and by clinic, chest x-rays and thoraco-abdominal scans in the experimental group. Patient-described quality of life (HRQoL) is a measure of three domains of perceived health: physical, social, and emotional. QoL is impacted by a medical condition or its treatment. Evidence suggests that lung cancer surgery has a significant impact on QoL. The objective of our work was to evaluate the influence of the type of surveillance on HRQoL in the population of the IFCT-0302 study.When an abnormal lung image is detected, its histological diagnosis is frequently obtained by transthoracic puncture guided by the scanner. The main complication of the procedure is pneumothorax. Hospital constraints do not allow all patients to be hospitalized after a transthoracic puncture. In this third axis, we worked on the validation of a predictive score for the occurrence of delayed pneumothorax after a CT-guided transparietal lung biopsy, in order to select patients who must be monitored in conventional hospitalization. This work was carried out on a cohort of patients from Besançon University Hospital, one part of the cohort having made it possible to develop the score, the other to validate it. Finally, external validation work on a cohort of patients from the Bichat – Claude Bernard Hospital was carried out
Тези доповідей конференцій з теми "Survie sans récidive":
Heluwaert, F., L. Renaud, L. Tracanelli, M. Abousalihac, A. Montchaud, E. Thimonier, I. Lienhart, et al. "Survie sans récidive à 3 ans et survie globale à 5 ans de la pose de prothese colique métallique auto-expansive en pont vers la chirurgie. Etude prospective monocentrique." In Journées Francophones d'Hépato-Gastroentérologie et d'Oncologie Digestive (JFHOD). Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1623378.